Menaquinone 4-d7
(Synonyms: 甲萘醌 4-d7) 目录号 : GC47619An internal standard for the quantification of menaquinone 4
Cas No.:1233937-25-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Menaquinone 4-d7 (MK-4-d7) is intended for use as an internal standard for the quantification of MK-4 by GC- or LC-MS. MK-4 is the predominant homolog of vitamin K2 and is composed of a naphthoquinone base with four isoprenoid units in the side chain.1 It is formed primarily via conversion of vitamin K1 in vivo and accumulates in various tissues, including the brain.2,3 MK-4 halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner.4 It also inhibits IκB kinase (IKK) activity, IκBα phosphorylation, and the transcriptional activity of NF-κB. Vitamin K2 may have a role in bone metabolism.1
1.Plaza, S.M., and Lamson, D.W.Vitamin K2 in bone metabolism and osteoporosisAltern. Med. Rev.10(1)24-35(2005) 2.Shearer, M.J., and Newman, P.Metabolism and cell biology of vitamin KThromb. Haemost.100(4)530-547(2008) 3.Okano, T., Shimomura, Y., Yamane, M., et al.Conversion of phylloquinone (vitamin K1) into menaquinone-4 (vitamin K2) in mice: Two possible routes for menaquinone-4 accumulation in cerebra of miceJ. Biol. Chem.283(17)11270-11279(2008) 4.Ozaki, I., Zhang, H., Mizuta, T., et al.Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor κB activationClin. Cancer Res.13(7)2236-2245(2007)
Cas No. | 1233937-25-1 | SDF | |
别名 | 甲萘醌 4-d7 | ||
Canonical SMILES | [2H]C1=C2C(C(C(C([2H])([2H])[2H])=C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)C2=O)=O)=C([2H])C([2H])=C1[2H] | ||
分子式 | C31H33D7O2 | 分子量 | 451.7 |
溶解度 | Chloroform: Slightly Soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2139 mL | 11.0693 mL | 22.1386 mL |
5 mM | 0.4428 mL | 2.2139 mL | 4.4277 mL |
10 mM | 0.2214 mL | 1.1069 mL | 2.2139 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。